Breast-Conserving Surgery with Radiation May Offer a Survival Advantage Over Mastectomy for Early-Stage Breast Cancer: What a 900,000-Patient Analysis Reveals

Table of Contents

• Key Points
• Background: Why This Research Matters
• Study Methods: How the Research Was Conducted
• Key Findings: The Main Results
• Subgroup Analyses: Specific Patient Populations
• Clinical Implications: What This Means for Patients
• Limitations: What This Study Could Not Prove
• Recommendations: What Patients Should Know
• Frequently Asked Questions
• Source Information

Key Points

• A meta-analysis of 35 studies and 909,077 women found breast-conserving surgery with radiation was associated with 28% relative survival benefit over mastectomy.
• The evidence was rated very low certainty because all included studies were observational and had serious risk of bias.
• In triple-negative breast cancer, nine studies with 26,530 patients showed a survival advantage for breast-conserving surgery with radiation.
• Comparing breast-conserving surgery with radiation to mastectomy plus radiation still showed a survival benefit in nine studies of 218,392 patients.
• Women under 50 also appeared to have a survival advantage with breast-conserving surgery and radiation, based on ten studies of 63,976 patients.

Background: Why This Research Matters

Breast cancer is the most common cancer worldwide, with more than 2.2 million new cases diagnosed in 2020. For women diagnosed with early-stage breast cancer (stage 1 to 3), treatment is multimodal and may include chemotherapy, endocrine (hormone-blocking) therapy, and radiotherapy, but nearly all women will undergo surgery as part of their treatment.

Currently, mastectomy (removal of the entire breast) and breast-conserving surgery with adjuvant radiotherapy (BCS + RT, also known as lumpectomy followed by radiation) are offered to patients as comparable surgical options. This equivalence is based on results from two landmark randomized controlled trials (RCTs) conducted in the 1970s and 1980s, which showed similar long-term survival outcomes for both procedures.

Since those trials were conducted, however, breast cancer treatment has evolved dramatically. Advances in systemic anticancer therapy (drugs that travel through the bloodstream to reach cancer cells) and locoregional treatments (treatments focused on the breast and nearby lymph nodes) have changed outcomes. A large-scale observational study published recently hinted that BCS + RT may actually provide a survival benefit compared with mastectomy.

If breast-conserving surgery with radiation truly offers women superior oncological outcomes compared with mastectomy, the authors argue, this information should be shared with patients as a key part of the decision-making process — because it may impact women's treatment choices. The aim of this review was therefore to systematically identify, appraise, and summarize the most current literature on survival outcomes for mastectomy versus BCS + RT, providing up-to-date evidence to support informed decision-making for early-stage breast cancer.

Study Methods: How the Research Was Conducted

Eligibility Criteria

The researchers designed a rigorous review protocol before starting, which was prospectively registered in PROSPERO, the international prospective register of systematic reviews (registration number CRD42021248849), and reported according to the PRISMA guidelines. To be eligible, studies had to be RCTs or observational studies published between 1 January 2000 and 18 December 2023 that compared overall survival for women undergoing BCS + RT versus mastectomy (with or without radiotherapy) for primary unilateral unifocal stage 1–3 breast cancer, with surgery as the first treatment.

Importantly, only studies in which at least 95% of the breast-conserving surgery group actually received adjuvant radiotherapy were considered eligible, to ensure a fair comparison of the full BCS + RT approach. Studies published before 2000 were excluded because they were considered unlikely to reflect current treatment practice.

The exclusion criteria were extensive and carefully defined. The following categories were excluded:

• Letters, conference abstracts, reviews, and grey literature (due to difficulty assessing incomplete information)
• Studies not primarily comparing survival outcomes for BCS + RT versus mastectomy
• Studies with fewer than 10 participants
• Studies involving patients receiving neoadjuvant therapy (chemotherapy given before surgery)
• Studies of specific breast cancer populations, such as pregnancy-related breast cancer, occult primary breast cancer, bilateral breast cancer, inflammatory breast cancer, hereditary breast cancer, breast sarcomas, recurrent breast cancer, and rare subtypes
• Studies of patients not receiving standard of care (for example, radical mastectomy)
• Studies not published in English, not in humans, or with no oncological outcomes reported

Search Strategy

A systematic search was conducted on 18 December 2023 of three major medical databases: MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), and Embase. The search strategy was developed in collaboration with a specialist librarian and combined terms for "breast cancer" with terms for the surgical procedures of interest and "overall survival" as the outcome. Titles and abstracts were screened independently by two reviewers, with disagreements resolved through discussion with senior team members.

Data Extraction and Bias Assessment

A dedicated data extraction form was developed by a clinician and a methodologist with expertise in evidence synthesis. Data collected included study characteristics, type of study and data collection, study interval, population and setting, inclusion and exclusion criteria, sample size, treatment details, demographic data, statistical analysis methods, and reported overall survival. All completed extraction forms were double-checked by a second reviewer.

To assess the quality of included studies, the researchers used two validated tools:

• Risk of Bias 2 (RoB 2) for randomized controlled trials (though none were ultimately identified)
• ROBINS-I (Risk Of Bias In Non-randomized Studies of Interventions) for observational studies

Bias was evaluated by two independent reviewers, and the overall certainty of the evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) tool.

Statistical Analysis

All studies except those deemed to be at critical risk of bias were included in a quantitative meta-analysis. When studies reported on the same or overlapping patient populations (such as registry-based studies), the most recent and largest study was selected. The primary analysis used a random-effects model with a common-effect inverse-variance method to produce a combined hazard ratio. A fixed-effect model was also run as a sensitivity analysis (a way to test whether the statistical assumptions changed the results).

Four pre-planned subgroup analyses were conducted to explore survival outcomes in specific patient populations of interest:

1. Studies including only patients with triple-negative breast cancer
2. Studies comparing BCS + RT with mastectomy without radiotherapy
3. Studies comparing BCS + RT with mastectomy with radiotherapy
4. Studies of young patients (defined as those under 50 years old at diagnosis)

If studies reported outcomes other than hazard ratios and no data transformation was possible, they were excluded. All analyses were conducted using STATA 17 statistical software.

Key Findings: The Main Results

Study Selection

The search initially identified 11,750 abstracts after removing duplicates. Of these, 189 were selected for full-text review, and 108 papers ultimately met the inclusion criteria. Notably, one paper by Kim et al. (2021) reported separate analyses from two distinct databases and was therefore counted as two studies. No randomized controlled trials were identified in the search.

A total of 29 studies were excluded from the meta-analysis due to an overall critical risk of bias, 42 studies were excluded because they used overlapping study populations (meaning the same patients were counted more than once across different publications), and 3 studies were excluded because their results were incompatible with inclusion in the pooled analysis.

Characteristics of Included Studies

The 35 included studies consisted of:

• 11 multicentre observational studies
• 10 single-centre observational studies
• 14 registry-based observational studies

These studies reported survival outcomes for a combined total of 909,077 patients — with 546,687 patients undergoing BCS + RT and 362,390 patients undergoing mastectomy (with or without radiotherapy). The studies came from countries around the world, including the USA, Canada, the UK, Sweden, Norway, Denmark, Germany, Italy, Switzerland, Slovenia, South Korea, Japan, China, Egypt, Peru, Australia, Malaysia, Singapore, and Hong Kong, reflecting a truly global dataset.

One study used a propensity score-matched patient cohort (a statistical technique to make two treatment groups more comparable), and another study matched patients by age, year of surgery, number of positive axillary lymph nodes, and tumour subtype.

Primary Outcome: Overall Survival

The main random-effects model pooling all 35 studies found a clear overall survival advantage for patients undergoing BCS + RT compared with those undergoing mastectomy:

• Pooled HR 0.72 (95% confidence interval 0.68 to 0.75, P < 0.001, I² = 76.3%)

This means that, at any given point during follow-up, women who had breast-conserving surgery with radiation therapy were 28% less likely to have died than women who had a mastectomy.

The fixed-effect sensitivity analysis produced very similar results: HR 0.70 (95% c.i. 0.69 to 0.71, P < 0.001, I² = 76.3%), confirming that the finding was not dependent on the statistical model chosen. The I² value of 76.3% indicates substantial heterogeneity — meaning individual study results varied considerably, which the authors flagged as a concern.

Individual study results ranged from an HR of 0.35 (a 65% survival advantage for BCS + RT, reported by Sayed et al. in Egypt) to 1.19 (a 19% survival advantage for mastectomy, reported by Sun et al. in China). While most of the 35 studies found a survival benefit for BCS + RT, a few found no difference or a benefit for mastectomy, underscoring the importance of the pooled analysis to produce an overall estimate.

Among the largest studies contributing to the meta-analysis:

• Almahariq et al. (2020), USA: 231,642 patients, HR 0.71 (95% c.i. 0.69 to 0.73)
• Chu et al. (2022), USA: 214,128 patients, HR 0.69 (95% c.i. 0.66 to 0.72)
• Grover et al. (2017), USA: 150,171 patients, HR 0.73 (95% c.i. 0.70 to 0.75)
• Lagendijk et al. (2018), Netherlands: 129,692 patients, HR 0.72 (95% c.i. 0.70 to 0.74)
• de Boniface et al. (2021), Sweden: 48,986 patients, HR 0.64 (95% c.i. 0.60 to 0.68)

Subgroup Analyses: Specific Patient Populations

Triple-Negative Breast Cancer

Nine studies with a total of 26,530 patients (13,060 undergoing mastectomy and 13,470 undergoing BCS + RT) reported survival specifically for patients with triple-negative breast cancer. All had a serious overall risk of bias. The results showed a similar survival benefit for BCS + RT in this aggressive breast cancer subtype:

• HR 0.73 (95% c.i. 0.68 to 0.79, P < 0.001, I² = 0.0%)

The I² value of 0.0% is notable — it indicates that there was essentially no statistical heterogeneity between these nine studies, making this a particularly consistent result.

BCS + RT versus Mastectomy Without Radiotherapy

A total of 21 studies including 688,394 patients compared overall survival for 467,283 patients undergoing BCS + RT versus 221,111 patients undergoing mastectomy without any radiotherapy. This comparison is important because many patients who choose mastectomy do not receive post-operative radiation, whereas BCS + RT always includes it.

The analysis again demonstrated a survival benefit for the BCS + RT group:

• HR 0.70 (95% c.i. 0.65 to 0.75, P < 0.001, I² = 84.2%)

BCS + RT versus Mastectomy With Radiotherapy

Nine studies, including a total of 218,392 patients, specifically compared women undergoing BCS + RT (194,368 patients) with women undergoing mastectomy followed by chest wall radiotherapy (24,024 patients). This is a more direct comparison because both groups received radiation treatment. Even in this head-to-head comparison, the survival benefit remained:

• HR 0.74 (95% c.i. 0.66 to 0.83, P < 0.001, I² = 69.4%)

Young Patients (Under Age 50)

A total of 10 studies including 63,976 younger women reported overall survival for those under 50 years old at diagnosis — 36,658 who underwent BCS + RT and 27,318 who underwent mastectomy. Three additional studies that were excluded from the main meta-analysis due to overlapping registry data were added to this subgroup analysis for a more complete picture. The results in this younger population were consistent with the overall findings, showing a survival advantage for breast-conserving surgery with radiation in this age group as well.

Clinical Implications: What This Means for Patients

These findings challenge the long-held assumption that mastectomy and BCS + RT are exactly equivalent in terms of survival. For decades, women have been told that both surgical options offer the same long-term outcomes, with the choice being largely a matter of personal preference, body image considerations, and the need for radiation therapy.

The authors of this meta-analysis suggest that if BCS + RT truly offers superior oncological outcomes — a survival benefit of roughly 28% relative improvement — this information should be shared with patients as a key part of the decision-making process. For many women, this could meaningfully impact their treatment choice.

It is important to note, however, that the evidence is drawn from observational (non-randomized) studies. This means the results reflect real-world treatment patterns rather than the controlled conditions of a randomized trial. The authors emphasize that the overall certainty of the evidence is "very low" by GRADE criteria, and they explicitly state that the results "should be interpreted with caution" — while still being shared with patients to support informed surgical decision-making.

For patients, this suggests several practical takeaways:

• Modern survival data should be part of the surgical consultation. Many clinical teams may still be quoting the old randomized trials from the 1970s and 1980s as the definitive evidence.
• If you are offered both surgery options, asking your surgeon about the most recent survival data is a reasonable and important question.
• The survival benefit seen with BCS + RT does not necessarily mean that mastectomy is a "bad" choice — many patients have strong personal reasons for choosing mastectomy, including genetics, anxiety about recurrence, or the desire to avoid radiation sessions.
• Individual factors matter enormously: tumour biology, stage, age, genetic status (for example, BRCA mutations), and overall health should all factor into the decision.

Limitations: What This Study Could Not Prove

While the scale of this meta-analysis is impressive, the authors are transparent about its limitations, and these caveats are essential for patients to understand:

• No randomized trials. The search identified no RCTs comparing these treatments in the modern era. All 35 included studies were observational, meaning patients were not randomly assigned to treatment groups. Women who choose BCS + RT may differ systematically from those who choose mastectomy in ways that affect survival (for example, age, overall health, tumour biology, or personal preferences).
• All studies had serious risk of bias. All 35 studies were rated as having a serious overall risk of bias using the ROBINS-I tool, and 34 of 35 were at high risk of bias due to confounding — a situation where other factors, not the surgery itself, may explain the survival differences.
• Very low certainty of evidence. Using the GRADE framework, the overall certainty of the evidence was rated "very low" due to the serious risk of bias and the substantial inconsistency between studies (I² = 76.3%).
• Confounding factors. It is possible that healthier patients, or those with less aggressive tumours, are more likely to be offered breast-conserving surgery, which would inflate the apparent survival benefit even if the surgical approach itself made no difference.
• Heterogeneity. The individual studies varied widely in design, geography, treatment era, follow-up duration, and patient populations. While the pooled estimate favours BCS + RT, some individual studies found no difference or even favoured mastectomy.
• Overlapping populations. Many of the studies relied on the same cancer registries. Although the authors removed overlapping datasets to minimize double counting, this is an imperfect process.
• Treatment era differences. Although the review covered studies published between 2000 and 2023, some studies included patients treated in the 1990s. Systemic therapy (chemotherapy, hormonal therapy, HER2-targeted therapy) has advanced rapidly, and outcomes for both surgical approaches have improved over time.

In plain terms: this analysis provides strong suggestive evidence that BCS + RT is at least not inferior — and may indeed be superior — to mastectomy in terms of survival, but it cannot prove cause and effect. Only a large, modern randomized controlled trial could definitively answer the question.

Recommendations: What Patients Should Know

For women newly diagnosed with early-stage breast cancer, surgical decision-making is deeply personal. Based on this study, here is what the authors and a balanced reading of the evidence suggest:

1. Ask your surgeon about modern survival data. The evidence base from the 1970s and 1980s randomized trials may be outdated. Real-world data from over 900,000 patients suggests breast-conserving surgery with radiation may offer a survival advantage.
2. Understand that both options remain valid. This meta-analysis does not say that mastectomy is a poor treatment. It says that, on average, across large populations, women who had BCS + RT lived longer. Individual outcomes vary, and some women are not good candidates for breast conservation (for example, those with large tumours relative to breast size, certain genetic predispositions, or contraindications to radiation).
3. Consider the full picture. Age, tumour stage, biological subtype (hormone receptor status, HER2 status, triple-negative status), genetic risk, and your own values and lifestyle should all factor into your decision. The subgroup analysis showed benefit for BCS + RT across triple-negative disease and younger women, but these findings should be discussed in the context of your specific situation.
4. Don't make the decision on survival data alone. While survival is the most important outcome for many patients, quality of life, body image, recovery time, the burden of daily radiation sessions, and anxiety about retaining breast tissue also matter. Acknowledge these factors with your care team and your loved ones.
5. Seek multidisciplinary input. The decision should involve your breast surgeon, radiation oncologist, and medical oncologist working together, since their combined perspective gives the most complete picture of your prognosis and treatment options.
6. Know that this evidence should be shared with you. The authors of this study explicitly conclude that "these results should be shared with patients to support informed surgical decision-making." If you are weighing surgery options, you are entitled to this information.

Ultimately, the takeaway from this meta-analysis of over 900,000 patients is hopeful and informative: breast-conserving surgery followed by radiation appears to offer at least as good — and possibly better — long-term survival compared with mastectomy for early-stage breast cancer. Women should feel empowered to discuss this modern evidence with their medical teams and make the choice that feels right for them, in the knowledge that choosing lumpectomy over mastectomy is not choosing a lesser outcome. On the contrary, the current evidence suggests it may come with a small survival benefit while preserving more of the natural breast.

Frequently Asked Questions

What did this new analysis compare?

This analysis pooled 35 observational studies following 909,077 women with early-stage breast cancer. It compared long-term survival after breast-conserving surgery with radiation therapy (BCS+RT) versus mastectomy. The combined result showed a 28% relative survival advantage for BCS+RT, but the evidence was rated very low certainty due to limitations.

Should this change my surgical treatment choice?

The study authors say these results should be shared with patients to support informed surgical decision-making. Both options remain valid. Women are encouraged to ask their surgeon about modern survival data and to consider individual factors like tumor biology, age, genetics, and personal preferences when making their choice.

Why is this evidence considered very low certainty?

All 35 studies were observational, meaning patients were not randomly assigned. Each study had a serious risk of bias, and results varied substantially. There were no modern randomized trials, and factors other than surgery itself, such as overall health or tumor aggressiveness, may explain some survival differences.

Does breast-conserving surgery with radiation offer better survival for triple-negative breast cancer?

In nine studies involving 26,530 patients with triple-negative breast cancer, breast-conserving surgery with radiation was associated with a survival advantage compared with mastectomy. The result was consistent across these studies, but all had a serious risk of bias, so the evidence is not definitive.

Is breast-conserving surgery with radiation better than mastectomy even when mastectomy includes radiation?

Nine studies including 218,392 patients directly compared breast-conserving surgery with radiation to mastectomy followed by chest wall radiation. The analysis still showed a survival benefit for the breast-conserving surgery group. However, this evidence also comes from observational studies with serious bias and very low certainty.

What does this analysis show for women under age 50?

Ten studies covering 63,976 women under 50 found a survival advantage for breast-conserving surgery with radiation compared with mastectomy in this young age group. These findings were consistent with the overall results, but they should be discussed with your healthcare team in the context of your specific situation.

What are the main limitations of this meta-analysis?

No randomized trials were found; all included studies were observational with serious risk of bias. Results varied widely, and confounding factors may explain some survival differences. Studies also came from different eras and overlapping registries. Therefore, this analysis cannot prove that breast-conserving surgery causes better survival.

Should I get a second opinion before choosing mastectomy or breast-conserving surgery with radiation for early-stage breast cancer?

Before finalizing a surgical plan for early-stage breast cancer, a second opinion can be valuable. Recent data from over 900,000 women shows a 28% relative survival advantage for breast-conserving surgery with radiation compared with mastectomy (hazard ratio 0.72), though this evidence comes from observational studies and is rated very low certainty. Because both options are still commonly presented as equivalent, an independent review of your pathology and treatment plan can help ensure you have heard the latest survival information and that breast conservation is considered if appropriate. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis.

Authors: Rajan KK, Fairhurst K, Birkbeck B, Novintan S, Wilson R, Savović J, Holcombe C, Potter S.

Journal: BJS Open, 2024, Volume 8, Issue 3, article zrae040

DOI: https://doi.org/10.1093/bjsopen/zrae040

Presentation: Presented as a Spotlight Poster discussion at the San Antonio Breast Cancer Symposium (December 2022) and as an oral presentation at the Association of Breast Surgery Conference, Belfast (May 2023).

Affiliations: Bristol Medical School, University of Bristol; Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust; Linda McCartney Centre, Liverpool University Hospitals NHS Trust; NIHR Applied Research Collaboration West; Bristol Breast Care Centre, North Bristol NHS Trust, UK.

This patient-friendly article is based on peer-reviewed research. It is intended for informational purposes only and does not constitute medical advice. Patients should discuss their individual treatment options with their healthcare team.